News Archive: January 2026

All peptide regulatory news from January 2026.

31 Articles in January 2026

Industry News January 27, 2026

AKS Claims Allowed in D. Nev. Compounding Pharmacy Fraud Case

AKS Claims Proceed Against Compounding Pharmacy Accused of Kickbacks In a significant development for the pharmaceutical industry, a federal court in Nevada has ruled that claims under the Anti-Kickback Statute (AKS) can proceed against a compounding pharmacy accused of engaging in illegal kickback...

Industry News January 27, 2026

Health Law Alliance Appoints Dr. Martha Rumore as Of Counsel

Health Law Alliance Welcomes Compounding Expert Pharmacist-Attorney Dr. Martha Rumore as Of Counsel The Health Law Alliance has announced the appointment of Dr. Martha Rumore, a noted expert in pharmaceutical compounding and a licensed attorney, as Of Counsel.

Industry News January 27, 2026

Compounding Pharmacy Sues Lilly, Novo for GLP-1 Drug Monopoly

Lilly, Novo Sued Over GLP-1 Drug Dominance by Compounding Pharmacy In a significant legal development, pharmaceutical giants Eli Lilly and Novo Nordisk are facing a lawsuit from a compounding pharmacy that accuses them of monopolistic practices in the market for GLP-1 receptor agonists, a class of ...

Industry News January 26, 2026

Telehealth Exclusivity Wars Heat Up: GLP-1 Compounder Lawsuit

GLP-1 Compounder Lawsuit Highlights Telehealth Exclusivity Wars In a significant legal development affecting the peptide industry, a lawsuit involving a compounding pharmacy that produces GLP-1 (glucagon-like peptide-1) medications has brought to light the escalating competition over telehealth exc...

Enforcement Actions January 26, 2026

Criminal Prosecutions in the Peptide Industry: Recent Cases

The peptide industry, once a niche segment within the broader pharmaceutical landscape, has seen exponential growth over recent years.

State Laws January 26, 2026

Arizona Medical Board Guidelines for Peptide Therapy

As the therapeutic use of peptides expands across the United States, regulatory guidelines are evolving to keep pace with innovations in medical treatments.

Industry News January 26, 2026

Telemedicine Peptide Clinics Face New Compliance Requirements

In the evolving landscape of healthcare, telemedicine has emerged as a pivotal component, offering patients unprecedented access to medical services.

Enforcement Actions January 26, 2026

FDA Import Alerts Affecting Peptide Research Chemicals

The landscape of peptide research chemicals is evolving rapidly, driven by scientific advancements and increasing interest in their potential therapeutic applications.

State Laws January 26, 2026

California Peptide Regulations: Complete Legal Guide for 2025

As the global focus on personalized medicine and biotechnology sharpens, peptides have emerged as pivotal players in the pharmaceutical and research sectors.

Legal Analysis January 26, 2026

Tirzepatide Compounding: Legal Gray Areas Explained

In recent years, the compounding of peptides like Tirzepatide has become a topic of significant debate and intrigue within the pharmaceutical and healthcare industries.

Industry News January 26, 2026

Major Peptide Supplier Faces Regulatory Action: Industry Impact

The peptide industry, a cornerstone of modern biomedical research and therapeutic development, is experiencing a seismic shift as one of its major suppliers faces significant regulatory action.

Federal Regulations January 26, 2026

FDA Warning Letters to Peptide Suppliers: 2024-2025 Trends

In recent years, the peptide industry has witnessed significant growth, fueled by the potential therapeutic benefits of peptides in treating a wide array of conditions.

State Laws January 26, 2026

New York State Regulations on Peptide Prescribing

As the pharmaceutical and biotechnology industries continue to innovate, peptide-based treatments have emerged as a promising frontier in medicine.

Industry News January 26, 2026

International Peptide Regulations: How US Laws Compare

In the rapidly evolving world of biotechnology and pharmaceuticals, peptides are gaining unprecedented attention due to their potential in treating a range of conditions from metabolic disorders to cancer.

Federal Regulations January 26, 2026

FDA Crackdown on Compounded Semaglutide: What You Need to Know

The increasing popularity of semaglutide, a medication initially developed to treat type 2 diabetes and later approved for weight management, has led to a surge in its use and a corresponding rise in the compounding of this peptide by pharmacies.

Industry News January 26, 2026

Peptide Market Shifts as Regulatory Pressure Increases

The peptide market, a cornerstone of modern pharmaceutical innovation, is experiencing a seismic shift as regulatory pressures intensify globally.

Federal Regulations January 26, 2026

How FDA Defines "Drug" vs "Research Chemical" for Peptides

In an era where scientific advancements have propelled peptides to the forefront of medical research, the distinction between a "drug" and a "research chemical" becomes crucial for researchers, pharmaceutical companies, and regulatory bodies.

Legal Analysis January 26, 2026

Research Peptide Disclaimers: Do They Provide Legal Protection?

In recent years, research peptides have gained significant attention within the scientific community, offering promising avenues for medical advancements and therapeutic interventions.

State Laws January 26, 2026

State-by-State Guide: Where Are Peptides Legal in 2025?

As the demand for peptides continues to grow in the realms of research and therapeutic applications, understanding the legal landscape surrounding these compounds is crucial for researchers, clinicians, and patients alike.

Legal Analysis January 26, 2026

WADA and Sports Law: Peptides in Athletic Competition

The intersection of athletic competition and pharmacological enhancement has been a focal point of sports law and ethics for decades.

State Laws January 26, 2026

Texas Pharmacy Board Stance on Compounded Peptides

In recent years, the use of compounded peptides has surged in popularity due to their potential therapeutic benefits.

State Laws January 26, 2026

Florida Laws on Peptide Therapy Clinics and Telemedicine

As the landscape of healthcare evolves, peptide therapy has emerged as a promising frontier in personalized medicine. Particularly in Florida, a state known for its burgeoning healthcare sector, peptide therapy clinics are on the rise.

Enforcement Actions January 26, 2026

Recent DOJ Actions Against Illegal Peptide Distributors

The peptide industry, a burgeoning sector due to the potential therapeutic benefits of peptides in treating various diseases, finds itself under scrutiny as the U.S. Department of Justice (DOJ) intensifies its actions against illegal distributors.

Legal Analysis January 26, 2026

Personal Importation of Peptides: FDA Guidelines and Risks

The world of pharmaceuticals is evolving, with peptides gaining significant attention in recent years due to their therapeutic potential.

Enforcement Actions January 26, 2026

Warning Letter Analysis: Common Violations by Peptide Companies

In the fast-evolving landscape of pharmaceuticals, peptides have emerged as a crucial segment due to their potential in treating a wide range of conditions.

Legal Analysis January 26, 2026

The Legal Status of BPC-157: Not FDA Approved But Not Illegal?

In the rapidly evolving landscape of peptide research and application, BPC-157 stands out as a compound of significant interest. Despite its growing popularity, its legal status remains a topic of debate and confusion.

Enforcement Actions January 26, 2026

Customs Seizures of Imported Peptides: Legal Implications

The importation of peptides into the United States has seen a marked increase, driven by the burgeoning interest in their potential therapeutic applications. However, this trend has also led to a rise in customs seizures of these substances.

Industry News January 26, 2026

Compounding Pharmacy Industry Responds to GLP-1 Regulations

The compounding pharmacy industry is currently navigating a complex regulatory landscape, especially in light of recent changes to the guidelines surrounding the compounding of GLP-1 (glucagon-like peptide-1) receptor agonists.

Federal Regulations January 26, 2026

GLP-1 Drug Shortage and FDA Compounding Guidelines Explained

In recent years, the pharmaceutical landscape has been significantly impacted by the emergence of GLP-1 receptor agonists, a class of drugs primarily used to treat type 2 diabetes and obesity.

Industry News January 26, 2026

Insurance Coverage for Peptide Therapy: Legal and Policy Updates

In recent years, peptide therapy has emerged as a promising treatment option in various medical fields, including endocrinology, dermatology, and neurology.

Federal Regulations January 26, 2026

FDA Enforcement Actions Against Peptide Sellers: Case Studies

In recent years, the peptide industry has witnessed significant growth, driven by advancements in biotechnology and increased interest in personalized medicine.